Cocrystal Pharma, Inc.

NasdaqCM:COCP Stock Report

Market Cap: US$22.1m

Cocrystal Pharma Future Growth

Future criteria checks 0/6

Cocrystal Pharma's earnings are forecast to decline at 15.1% per annum. EPS is expected to decline by 14.4% per annum.

Key information

-15.1%

Earnings growth rate

-14.4%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19
We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19
Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06
We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05
We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13
Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24
What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20
Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Earnings and Revenue Growth Forecasts

NasdaqCM:COCP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-26N/AN/A1
12/31/2025N/A-23N/AN/A2
12/31/2024N/A-20N/AN/A3
9/30/2024N/A-19N/AN/AN/A
6/30/2024N/A-18-14-14N/A
3/31/2024N/A-17-16-16N/A
12/31/2023N/A-18-15-15N/A
9/30/2023N/A-18-16-16N/A
6/30/2023N/A-20-23-22N/A
3/31/2023N/A-40-21-21N/A
12/31/2022N/A-39-22-21N/A
9/30/2022N/A-38-20-19N/A
6/30/2022N/A-36-16-16N/A
3/31/2022N/A-16-15-15N/A
12/31/2021N/A-14-13-13N/A
9/30/20211-12-12-12N/A
6/30/20211-11-10-10N/A
3/31/20212-10-10-9N/A
12/31/20202-10-10-10N/A
9/30/20202-56-9-9N/A
6/30/20202-55-7-7N/A
3/31/20202-53-6-6N/A
12/31/20197-48-2-2N/A
9/30/20196-45-2-2N/A
6/30/20196-45-3-3N/A
3/31/20195-45-4-4N/A
12/31/2018N/A-49-8-8N/A
9/30/2018N/A0-8-8N/A
6/30/2018N/A0N/A-8N/A
3/31/2018N/A0N/A-7N/A
12/31/2017N/A-1N/A-7N/A
9/30/2017N/A-72N/A-8N/A
6/30/2017N/A-71N/A-9N/A
3/31/2017N/A-73N/A-13N/A
12/31/2016N/A-75N/A-15N/A
9/30/2016N/A-40N/A-15N/A
6/30/20160-38N/A-15N/A
3/31/20160-38N/A-13N/A
12/31/20150-50N/A-10N/A
9/30/20150-22N/A-9N/A
6/30/20150-24N/A-7N/A
3/31/20150-16N/A-6N/A
12/31/201400N/A-6N/A
9/30/2014N/A1N/A-5N/A
6/30/2014N/A3N/A-5N/A
3/31/2014N/A-3N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COCP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: COCP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: COCP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if COCP's revenue is forecast to grow faster than the US market.

High Growth Revenue: COCP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if COCP's Return on Equity is forecast to be high in 3 years time


Discover growth companies